Akums reports Q4 FY25 with 12.4% revenue growth
Akums invested Rs. 272 crore in capital expenditure during FY25
Akums invested Rs. 272 crore in capital expenditure during FY25
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
The CDMO upgrade represents a transformational step for Remedium Lifecare
EBITDA before special items decreases to €4.08 billion (7.4%)
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
Subscribe To Our Newsletter & Stay Updated